Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Nutriband elects seven directors and raises authorized preferred shares to 20 million

At the annual general meeting, shareholders elected seven directors for one year and confirmed Sadler, Gibb & Associates as auditors. The number of authorized preferred shares was increased from 10 million to 20 million; the advisory vote on executive compensation was approved to be held annually. The board also appointed Alessandro Puddu and Viorica Carlig, and the company announced the sale of 90% of subsidiary Pocono Pharmaceutical to EarthVision for $5 million as well as a letter of intent with the Qvanta Group to explore quantum-AI cooperation. Nutriband continues work on the Aversa fentanyl patch, while for 2026 a loss per share of -$0.61 is forecast despite an expected 28% increase in revenue. » More on de.investing.com
Nutriband appoints two directors and reports progress on Aversa fentanyl patch

Nutriband has appointed Alessandro Puddu and Viorica Carlig to its board of directors and reports key milestones for the Aversa fentanyl patch, including an enhanced partnership with Kindeva, scaling of the commercial manufacturing process, and a Type-C meeting with the FDA. For 2026 the company plans a full patent filing (protection possibly through 2046), production of study material, an IND submission, and the start of clinical studies on abuse potential. Financial data show a market capitalization of around $55 million, more cash than liabilities, and analyst forecasts for 2026 with EPS of -0.61; the stock trades well below its 52-week high. Nutriband has also filed a complaint with FINRA alleging naked short selling and notes outstanding warrant expiration dates in October 2026. » More on de.investing.com
Nutriband sells 90% of Pocono Pharmaceutical to EarthVision Bio — shares jump sharply

Nutriband sold a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million; the deal is expected to close by December 31, 2025. Nutriband shareholders are to retain a 10% stake in EarthVision Bio after the acquisition. Nutriband plans to use the proceeds to further develop its AVERSA fentanyl patch, which could have a potential U.S. annual sales range of $80–200 million; no development or launch timeline was given. The announcement triggered a 14.6% surge in the stock. » More on de.investing.com

Financials

In the last quarter, NUTRIBAND INC. DL -,001 Aktie had revenue of €369.52K and net profit of -€1.06M

(EUR)	Apr 2026	YoY
Revenue	369.52K	37.31%
Gross profit	167.79K	24.59%
Net profit	-1.06M	13.66%
EBITDA	-1.03M	12.39%

Fundamentals

Metric	Value
Market capitalization	€46.67M
Number of shares	12.16M
52-week high/low	€7.43 - €2.41
Dividends	No
Beta	1.97
P/E ratio	-1.70
PEG ratio	0.01
P/B ratio	9.05
P/S ratio	30.08

Company profile

Nutriband Inc. entwickelt ein Portfolio von transdermalen pharmazeutischen Produkten. Das führende Produkt in der Entwicklung ist AVERSA Fentanyl, ein transdermales Fentanylsystem zur Missbrauchsverhinderung, das Ärzten und Patienten ein transdermales Fentanylprodukt mit verlängerter Wirkstofffreisetzung zur Behandlung chronischer Schmerzen bietet, die eine Opioidtherapie rund um die Uhr erfordern. Das Unternehmen entwickelt auch andere Produkte, darunter AVERSA Buprenorphin und AVERSA Methylphenidat, Exenatide für Typ-2-Diabetes und follikelstimulierendes Hormon für Unfruchtbarkeit. Nutriband Inc. hat eine Lizenzvereinbarung mit Rambam Med-Tech Ltd. für die Entwicklung der RAMBAM Closed System Transfer Devices. Das Unternehmen wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Orlando, Florida.

Name	NUTRIBAND INC. DL -,001 Aktie
CEO	Gareth Sheridan
Headquarters	Orlando, fl USA
Website	nutriband.com
Sector	Industrials
Industry	Commercial Services & Supplies
IPO	10/01/2021
Employees	13